To include your compound in the COVID-19 Resource Center, submit it here.

Ambit's gambit

Cancer play Ambit withdraws IPO; garners more venture capital instead

The day after cancer play Ambit Biosciences Corp. withdrew an IPO, it revealed that existing investors had ponied up $30 million in a

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE